CAJ | 학술논문

目的证明HSP90α是否可以作为肺癌诊断的血清标志蛋白.方法利用SDS-PAGE和基质辅助解吸附时间飞行质谱(MALDI-TOF-MS),对具有不同转移能力的肺腺癌细胞系CL1-0(低转移)和CL1-5(高转移)的培养基上清进行分析,并对已鉴定的候选标志蛋白通过免疫印迹方法进行确定.此外,利用酶联免疫吸附技术(ELISA)对141例肺癌、37例良性肺病患者、及46例健康人血清对候选蛋白进行了进一步的分析.结果 HSP90α在CL1-5的培养基中高表达,进一步发现HSP90α在非小细胞肺癌的血清中特异性升高.当ROC曲线(receiver operating characteristic,ROC)临界值取为0.535时,HSP90α能区分肺癌以及良性肺病患者和健康人,其敏感性为0.817,特异性为0.919,总体精确性为80.14%.结论HSP90α有望成为区分肺癌、良性肺病患者和健康人以及肺癌分期诊断的血清标志蛋白.
목적 증명HSP90α시부가이작위폐암진단적혈청표지단백.방법 이용SDS-PAGE화기질보조해흡부시간비행질보(MALDI-TOF-MS),대구유불동전이능력적폐선암세포계CL1-0(저전이)화CL1-5(고전이)적배양기상청진행분석,병대이감정적후선표지단백통과면역인적방법진행학정.차외,이용매련면역흡부기술(ELISA)대141례폐암、37례량성폐병환자、급46례건강인혈청대후선단백진행료진일보적분석.결과 HSP90α재CL1-5적배양기중고표체,진일보발현HSP90α재비소세포폐암적혈청중특이성승고.당ROC곡선(receiver operating characteristic,ROC)림계치취위0.535시,HSP90α능구분폐암이급량성폐병환자화건강인,기민감성위0.817,특이성위0.919,총체정학성위80.14%.결론HSP90α유망성위구분폐암、량성폐병환자화건강인이급폐암분기진단적혈청표지단백.
Objective To investigate whether HSP90α could be a sensitive and specific serum biomarker for the diagnosis and progression of lung cancer. Methods In the present study, different secretomic analy-ses on the two human lung adenocarcinoma cell lines CL1-0 and CL1-5 with low and high metastatic poten-tial, respectively, were performed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and ma-trix-assisted laser desorption/ionization time-of-flight mass spectrometry. The candidate biomarker was con-firmed by Western blotting, and was further analyzed in 224 serum samples including 141 lung cancer, 37 benign pulmonary diseases, as well as 46 healthy individuals using ELISA assay. Results HSP90α was sig-nificantly upregulated in the CM of CL1-5 cells. It was found that the levels of HSP90α were specifically ele-vated in the sera of non-small cell lung cancer compared with other groups. At the cut-off point 0.535 on the receiver operating oharacteristie curve, HSP90α could comparatively discriminate lung cancer from benign lung disease and healthy control groups with sensitivity of 0. 817, specificity 0. 919 and total accuracy 80. 14%. Conclusion HSP90α may be a potential useful serum biomarker for discriminating lung cancer from benign lung diseases and healthy individuals and staging of non-small cell lung cancer.